Clinical Trials Sponsored by Protean BioDiagnostics

Total 182 results

Anthony Magliocco

Recruiting

Idylla EGFR Lung Trial

Lung Cancer | Oncology | Technology

United States
Proteon Therapeutics

Withdrawn

Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries

Peripheral Artery Disease

United States
Proteon Therapeutics

Completed

A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease (PRT-201-102)

Chronic Kidney Disease

United States
Proteon Therapeutics

Completed

A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

Chronic Kidney Disease

United States
Proteon Therapeutics

Completed

A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)

Chronic Kidney Disease

United States, Canada
Proteon Therapeutics

Completed

Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)

Peripheral Artery Disease

United States
Proteon Therapeutics

Completed

A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)

Chronic Kidney Disease

United States
Proteon Therapeutics

Completed

A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients

Chronic Kidney Disease

United States
Protein Supplies SL

Completed

Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment

Inflammation | Obesity

Spain
Protein Sciences Corporation

Completed

Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older (PSC26)

Influenza

United States
Protein Sciences Corporation

Completed

Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

Influenza

United States
Protein Sciences Corporation

Completed

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

Influenza

United States
Protein Sciences Corporation

Completed

Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV

Influenza

United States
Protein Supplies SL

Withdrawn

Cost-effectiveness Study of a Multidisciplinary Weight Loss Method to Improve the Health Condition of Obese Patients (PRONOCOST)

Obesity | Obese

Argentina
Protein Supplies SL

Completed

Structural Changes of Subcutaneous Tissue by Ultrasonographies in Patients After Treatment With PnKCelulitis® Program (PnKCelulitis)

Cellulite
Protein Supplies SL

Unknown

Study to Evaluate Effectiveness of a Weight Loss Program in Obese Patients During 3 Months Prior to Bariatric Surgery

Obesity, Morbid | Bariatric Surgery | Comorbidity
Protein Sciences Corporation

Completed

Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

Influenza

United States
Protein Sciences Corporation

Completed

Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age

Influenza

United States
Protein Sciences Corporation

Completed

Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics

Influenza

United States
Protein Supplies SL

Completed

MR Fat Quantification and Elastography During a Very Low-calorie-ketogenic Diet (Pronokal Method®) vs a Low Calorie Diet

Liver Fat
Protein Sciences Corporation

Completed

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults (PSC25)

Influenza

United States
Protein Sciences Corporation

Completed

Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

Influenza

United States
Protein Sciences Corporation

Completed

Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults

Influenza

United States
Sanofi
Protein Sciences Corporation

Completed

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

Influenza

United States
Tulane University
Ideal Protein

Completed

A Trial of the Ideal Protein System Versus Low Fat Diet for Weight Loss (RENEWAL)

Weight Loss

United States
Protgen Ltd

Completed

Phase II/III of Recombinant Human Serum Albumin

Hepatic Ascites

China
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer

Breast Cancer

China
Protgen Ltd

Unknown

Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
Protgen Ltd

Completed

Recombinant Human Serum Albumin in Healthy Subjects

Hepatic Ascites

China
Proteor Group

Completed

Above-knee Socket Evaluation : Sub-ischial vs Ischial Containment (P20-EMBSUBI)

Lower Limb Amputation Above Knee (Injury)

France
Protgen Ltd

Unknown

Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer

Non Small Cell Lung Cancer

China
Proteor Group

Recruiting

New Microprocessor-Controlled Prosthetic Knee Evaluation

Lower Limb Amputation Above Knee (Injury)

France
Protgen Ltd

Completed

Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects

Hepatic Ascites

China
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer

Liver Cancer

China
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Colorectal Cancer

Colorectal Cancer

China
Protgen Ltd

Unknown

Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure

Pancreatic Cancer

China
Protgen Ltd

Completed

Single-dose Escalation Trial of M2ES in Healthy Volunteer

Cancer
Protgen Ltd

Unknown

Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

China
Protein Sciences Corporation
Kaiser Permanente

Completed

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

Human Influenza

United States
Prothena Biosciences Ltd.

Terminated

Study in Subjects With Light Chain (AL) Amyloidosis

AL Amyloidosis

United States, Spain, Australia, Italy, Germany, Austria, Greece, France, Israel, United Kingdom
Washington University School of Medicine
National Marrow Donor Program; Predictive BioDiagnostics, LLC

Completed

Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant

Hematopoietic Stem Cell Transplantation | Stem Cell Transplantation, Hematopoietic | Transplantation, Hematopoietic Stem Cell

United States
Progen Pharmaceuticals

Completed

Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors

Cancer

United States
Progen Pharmaceuticals

Terminated

Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma (PATHWAY)

Cancer | Hepatocellular Carcinoma | Primary Liver Cancer | Liver Cancer | Hepatoma

Hong Kong, Singapore, United States, Australia, Canada, Italy, Malaysia, Spain, Taiwan, Thailand
Progen Pharmaceuticals

Completed

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Cancer

United States
Progen Pharmaceuticals

Completed

Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD

Age Related Macular Degeneration

United States, Mexico, Russian Federation
Prothena Biosciences Ltd.

Terminated

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis (VITAL)

Primary Systemic (AL) Amyloidosis

United States, Spain, Israel, Canada, Poland, Netherlands, France, Germany, United Kingdom, Belgium, Denmark, Greece, Australia, Austria, Italy
Protina Pharmazeutische GmbH

Completed

Magnesium Supplementation in Type II Diabetes

Effect of Magnesium in Diabetes

Germany
Prothena Biosciences Ltd.

Completed

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Primary Amyloidosis

United States
Prothena Biosciences Limited

Completed

Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis

Psoriasis

United States
Prothena Biosciences Limited

Completed

Single Ascending Dose Study of PRX003 in Healthy Subjects

Psoriasis

United States

3

Subscribe